PathologyLabTraining

Cytology and Cervical Screening Training for Biomedical Scientists

12 min read · Published: 2025-01-08 · Updated: 2026-06-08

Cytology is one of the most distinctive disciplines a biomedical scientist (BMS) can enter, sitting within Cellular Pathology and combining microscopy, molecular testing and a direct role in cancer prevention. The transition of the NHS Cervical Screening Programme (NHS CSP) to human papillomavirus (HPV) primary screening has reshaped the cytology workforce, moving the cytologist from a high-volume primary screener to a skilled triage and diagnostic specialist. This guide explains sample preparation, the current HPV-led pathway, reporting terminology and the IBMS training routes that take you from trainee to advanced practitioner across Bands 2 to 8.

What Cytology Covers: Cervical and Diagnostic

Cytology is the microscopic examination of individual cells to detect malignant, pre-malignant and benign conditions. In UK practice it splits into two broad streams, and a confident BMS understands both.

The Royal College of Pathologists (RCPath) publishes tissue pathways and datasets for diagnostic cytopathology, and several internationally standardised reporting systems are now embedded in UK practice, including the Milan System for salivary gland cytopathology, the Paris System for urinary cytology, the Bethesda System for thyroid FNA and the International System for serous effusions. Familiarity with these structured frameworks is increasingly expected at senior level because they standardise risk of malignancy and downstream management.

Sample Preparation and Liquid-Based Cytology

Liquid-based cytology (LBC) replaced the conventional smear across the UK and remains the standard preparation for cervical samples. Instead of smearing cells directly onto a slide, the sample-taker rinses or detaches the collection device into a vial of preservative fluid. This single change brought major quality gains: simultaneous fixation, fewer obscuring red cells and inflammatory exudate, a near-monolayer of well-preserved cells, and crucially a residual sample suitable for reflex HPV and molecular testing.

Two LBC systems are used in the NHS:

| Feature | ThinPrep | SurePath | |---|---|---| | Principle | Filter transfer of cells onto slide | Density-gradient enrichment and sedimentation | | Core equipment | Processor with polycarbonate filters | Robotic pipettor and centrifuge | | Minimum adequate squamous cell count | ~5,000 cells | ~15,000 cells | | Vial fixative | Methanol-based | Ethanol-based |

The minimum cell-count thresholds above are the figures used to balance a low inadequate rate against reliable detection of abnormality. Adequacy assessment is a core BMS competency: an inadequate sample (insufficient cells, obscuring blood or inflammation, or poor preservation) must be reported as such and the patient recalled.

For diagnostic cytology, preparation is broader and more hands-on. The BMS may produce direct smears, cytospins for low-cellularity fluids such as CSF, LBC preparations, and cell blocks. Cell blocks are particularly important because they allow immunohistochemistry (IHC) and molecular testing on cytology material, supporting precision-oncology decisions. Many of the staining and morphology skills overlap with immunohistochemistry technique training and the wider workflow described in microtomy and tissue processing training. Papanicolaou (Pap), May-Grünwald-Giemsa and Romanowsky stains are mainstays, and toluidine blue is used for rapid on-site evaluation (ROSE) of FNAs.

The Move to HPV Primary Screening

Since December 2019, every routine cervical sample in England has been tested first for high-risk HPV (hrHPV) rather than examined first under the microscope. HPV primary screening is more sensitive and more reproducible than cytology-led screening, and it underpins the most significant change to the workforce in a generation. The devolved nations operate equivalent HPV-primary programmes.

The current pathway works as follows:

1. hrHPV test on the LBC sample. Validated molecular assays (for example, Roche cobas and equivalent platforms) detect a panel of high-risk genotypes, often with separate genotyping for HPV 16 and 18. 2. hrHPV not detected. The participant returns to routine recall. No cytology is performed. 3. hrHPV detected. Reflex cytology (triage) is performed on the same residual LBC sample. Any grade of abnormal cytology (borderline change or worse) results in immediate colposcopy referral. 4. hrHPV positive but cytology negative. The participant is recalled for a repeat HPV test at 12 months to confirm clearance or persistence; persistent hrHPV positivity at later repeats leads to colposcopy regardless of the cytology result.

This is the central point for trainees to grasp: under HPV primary screening, cytology is a triage test, not a screening test. The molecular result determines whether a slide is ever examined. Workload has fallen and changed in character, with each examined slide more likely to harbour abnormality, demanding sustained morphological expertise. The HPV step also connects cytology to wider molecular practice covered in molecular diagnostics and PCR training.

Screening Intervals and the 2025 Changes

The NHS CSP invites people with a cervix aged 25 to 64, with the first invitation issued shortly before the 25th birthday (around age 24.5). Recall intervals were updated in 2025 on the strength of evidence that an hrHPV-negative result confers very low cervical cancer risk for around a decade.

Self-sampling for HPV is being introduced to reach people who do not attend conventional screening, with self-collected samples processed for HPV testing. Trainees should track programme communications, as the role of self-sampling within the formal recall algorithm continues to evolve. Always defer to the current NHS CSP guidance and UK Health Security Agency (UKHSA) publications rather than older textbooks.

Reporting Terminology: BSCC and the ABC Categories

UK cervical cytology is reported using terminology developed by the British Society for Clinical Cytology (BSCC) and codified in the NHS CSP guidance commonly referred to as the "Achievable Standards, Benchmarks for reporting and Criteria for evaluating cervical cytopathology" (the ABC document, currently in its third edition, ABC3). The unit of abnormality is dyskaryosis, which maps to the Bethesda squamous intraepithelial lesion (SIL) terminology and, predictively, to histological cervical intraepithelial neoplasia (CIN).

| Cytology result (BSCC/ABC) | Bethesda equivalent | Approximate histology | Typical action under HPV triage | |---|---|---|---| | Negative | NILM | Normal | Recall per HPV result | | Inadequate | Unsatisfactory | n/a | Repeat sample | | Borderline change, squamous | ASC-US | Reactive/uncertain | Colposcopy referral | | Borderline change, endocervical | AGC | Uncertain glandular | Colposcopy referral | | Low-grade dyskaryosis | LSIL | CIN 1 | Colposcopy referral | | High-grade dyskaryosis (moderate) | HSIL | CIN 2 | Colposcopy referral | | High-grade dyskaryosis (severe) | HSIL | CIN 3 | Colposcopy referral | | High-grade dyskaryosis / ?invasive | HSIL / ?carcinoma | ?Invasive SCC | Urgent colposcopy | | ?Glandular neoplasia of endocervical type | AGC / AIS | CGIN / adenocarcinoma | Urgent specialist referral |

Borderline categories signal changes that fall short of dyskaryosis but cannot be confidently called negative. "?Glandular neoplasia" is reported with care because cervical glandular intraepithelial neoplasia (CGIN) and adenocarcinoma are easily missed and carry serious consequences if overlooked. Diagnostic cytology uses different, site-specific terminology drawn from the international systems noted earlier, each tied to a defined risk of malignancy.

The Cytology Workforce Role and BMS Responsibilities

The cytology team is multidisciplinary and grade-banded. A typical NHS structure includes:

Quality is non-negotiable in this discipline. All cervical cytology reporters must meet minimum annual screening volumes, participate in accredited gynaecological cytopathology external quality assessment (EQA), and work within laboratories accredited to ISO 15189:2022 and inspected by the United Kingdom Accreditation Service (UKAS), as explained in the UKAS ISO 15189 accreditation guide. Failsafe processes, rapid review, primary screener and checker workflows, and cytology-histology correlation all protect against false-negative reporting. When discrepancies arise, structured investigation is expected, drawing on the principles in root cause analysis and CAPA training.

IBMS and RCPath Training Routes

Cytology has a clearly mapped progression. All practising cytologists must be registered with the Health and Care Professions Council (HCPC), normally achieved via the IBMS Registration Portfolio and HCPC route.

1. Foundation knowledge. Trainees complete underpinning theory and attend an NHS CSP-approved training centre. Approved centres provide intensive, often residential, courses early in training. 2. Certificate of Competence in Cervical Cytology. This NHS CSP-recognised qualification (delivered through the IBMS, historically alongside the City & Guilds route) certifies competence to screen cervical cytology under supervision and is the gateway requirement for screener roles. 3. IBMS Advanced Specialist Diploma (ASD) in Cervical Cytology. This demonstrates the scientific knowledge and practical competence to screen, interpret and report normal and abnormal cervical cytology. Entry requires IBMS membership, HCPC registration and the relevant certificate of competence. 4. IBMS Diagnostic Cytopathology qualifications. These extend competence into non-gynaecological cytology, FNA and the international reporting systems, supporting roles in diagnostic cytology and advanced practice.

Training is heavily portfolio- and assessment-driven, combining on-the-job evidence, external examinations and continued EQA participation. Progression aligns with broader BMS development such as the IBMS Specialist Portfolio and, for advanced practice, exam preparation that may include practical assessment styles described in OSPE and OSCE preparation training. Finding a suitable training laboratory is the first practical step; see finding an IBMS-approved laboratory.

Frequently Asked Questions

Is cervical cytology being phased out under HPV primary screening?

No. The role has changed rather than disappeared. Cytology is now a triage test performed on hrHPV-positive samples to decide on colposcopy referral, so although volumes have fallen, skilled morphological reporting remains essential. Diagnostic (non-gynaecological) cytology continues to grow in importance, particularly with cell-block techniques supporting molecular and immunohistochemical testing.

What qualification do I need to screen cervical cytology in the NHS?

You must hold an NHS CSP-recognised Certificate of Competence in Cervical Cytology, be HCPC-registered and be an IBMS member or fellow. Screeners then maintain competence through minimum annual screening volumes and ongoing participation in accredited gynaecological cytopathology EQA. Advanced reporting and authorisation require further qualifications such as the IBMS Advanced Specialist Diploma.

What is the difference between ThinPrep and SurePath?

Both are liquid-based cytology systems that produce a thin, well-preserved cell layer from a sample collected into preservative fluid. ThinPrep uses filter-based cell transfer with a minimum adequacy threshold of around 5,000 squamous cells, while SurePath uses density-gradient enrichment and sedimentation with a higher threshold of around 15,000 cells. Both leave a residual sample suitable for reflex HPV testing.

How does BSCC dyskaryosis terminology relate to the Bethesda system?

BSCC terminology describes squamous abnormality as dyskaryosis, graded as borderline, low-grade and high-grade (moderate or severe). These map closely to the Bethesda categories ASC-US, LSIL and HSIL respectively, and predict histological CIN 1, 2 and 3. UK laboratories report using the BSCC/ABC framework, but understanding the Bethesda equivalents is valuable for international literature and audit.

What happens if an hrHPV-positive sample is cytology-negative?

The participant is not immediately referred to colposcopy. Instead they are typically recalled for a repeat HPV test, usually around 12 months later, to determine whether the infection has cleared or persists. Persistent hrHPV positivity leads to further triage or colposcopy according to the current NHS CSP algorithm.

Can biomedical scientists report diagnostic (non-gynaecological) cytology?

Yes, within defined scope and with appropriate training. Suitably qualified and competency-assessed BMSs contribute to diagnostic cytology preparation, FNA support, rapid on-site evaluation and, at advanced levels, reporting using internationally standardised systems such as the Milan, Paris and Bethesda thyroid frameworks. Complex and definitive diagnoses are made within consultant-led teams.

Further training

Cytology sits within the wider NHS laboratory landscape. Start with the pillar guide to NHS Laboratory Training, then explore related disciplines and skills:

Related Articles